Alcohol use/abuse was not assessed but is often comorbid with and influences sleep problems[54] and is disproportionately prevalent among young adult populations.[55] Future research should consider whether potential group differences in substance use affect the roles of sleep and affective comorbidities in migraine. Incorporating daily sleep diary data would further strengthen the present design by allowing prospective examination of the sleep disturbance variables with new-onset migraine, although examining sleep as a trigger of individual headache attacks was not a goal of this study. Given that this

was not a treatment-seeking sample, we did not assess frequency of medication use for headache or insomnia, although future studies should consider incorporating these variables into similar analyses. Finally, given our broad interest in comparing aspects of sleep disturbance, we did not attempt to isolate the specific MLN0128 clinical trial contributors to poor sleep quality in particular, BVD-523 such as delayed sleep onset latency or shortened sleep duration, although their relation with headache-related variables merits future exploration. In light of our findings

and the stark paucity of data regarding the effects on migraine of treating comorbid psychiatric disorders, a strong need remains for treatment studies that assess the effects on migraine of comprehensive strategies to treat sleep disturbance and psychiatric comorbidities. (a)  Conception and Design (a)  Drafting the Manuscript

(a)  Final Approval of the Completed Manuscript “
“Epicrania fugax (EF) is a primary headache of recent description. We aimed to report 19 new cases of EF, and thus contribute to the characterization of this emerging headache. EF is characterized by painful paroxysms starting in a particular area of the head, and rapidly radiating forwards or backwards through the territories of different nerves. The pain is felt in quick motion along a lineal or zigzag trajectory. To date, 47 cases have been published, 34 with forward EF and 13 with backward EF. We performed a descriptive study of all EF cases attending our Headache Unit from April 2010 to December 2012. Demographic and clinical data were recorded with a structured questionnaire. Overall, there were 12 women and 7 men. Mean age at onset was 51.7 ± 16.2. Fourteen patients had Loperamide forward EF, while 5 patients had backward EF. Painful paroxysms lasted 1-4 seconds. Pain intensity was usually moderate or severe, and pain quality was mostly electric. Four patients had ocular autonomic accompaniments. Pain frequency was extremely variable, and 7 patients identified some triggers. Between attacks, 13 patients had some pain or tenderness in the stemming area. Thirteen patients required therapy for their pain. Neuromodulators, indomethacin, anesthetic blockades, and steroid injections were used in different cases, with partial or complete response.